A Phase 2 interventional study of IPI-145, a PI3K Inhibitor and Placebo to match IPI-145 in Asthma, sponsored by SecuraBio. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-03-17.
Sponsored by SecuraBio · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 385 studies in Asthma with a site in Germany — 20 open to participants now, 29 under way, 7 of them phase 3. Asthma · Germany.
Among the 385 studies in Asthma with a site in Germany, this one is the 258th largest by enrollment of the 338 interventional ones that give a count, is one of 32 that started in 2012, is one of 124 in phase 2, and was the 172nd registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →20 of the 385 studies in Asthma with a site in Germany are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Germany, Argentina, France and 7 more countries
Ages 12–17
Kymera Therapeutics, Inc. · Sites in Germany, United States, Poland and 1 more country
Ages 18+
Sanofi · Sites in Germany, United States, Canada and 3 more countries
Ages 6+
Chiesi Farmaceutici S.p.A. · Sites in Germany, Argentina, Bosnia and Herzegovina and 11 more countries
Ages 18–75
Generate Biomedicines · Sites in Germany, United States, Brazil and 18 more countries
Ages 12–80
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
385 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 130 · Phase 3 118 · Phase 4 31
First in 1996; this study’s year is marked. 32 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 209 across the 338 interventional studies, 239 across the 46 observational. Of the 350 that completed or were terminated, 180 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
331 of 385 have an industry lead sponsor. The 10 most frequent:
SecuraBio is the lead sponsor of 25 studies on the registry; 2 are open to participants now.
SecuraBio has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
10 of the studies in Asthma with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT05851443Incyte CorporationA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | 2026-11-20 |
| NCT05903001RWTH Aachen UniversityDiaphragmatic Function as a Biomarker | 2026-12-30 |
| NCT06317909Fraunhofer-Institute of Toxicology and Experimental MedicineDevelopment of a Novel Non-invasive Inflammometry Following Allergen Challenge in Patients With Mild Allergic Asthma | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 385 studies in Asthma with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the effects of multi-dose regimens of IPI-145 on lung function in mild asthmatic subjects following allergen challenge.
This is a phase 2a, randomized, double-blind, placebo-controlled, multi-dose, 2-way cross-over study designed to examine the effect of IPI-145 on lung function and inflammatory indices in mild, allergen-reactive asthmatic subjects undergoing allergen challenge.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Capsules
Drug: IPI-145, a PI3K Inhibitor · Drug: Placebo to match IPI-145
Capsules
Drug: IPI-145, a PI3K Inhibitor · Drug: Placebo to match IPI-145
Active drug
Comparator
Forced Expiratory Volume in one second (FEV1)
Time frame: Day 14
Maximum concentration (Cmax), Area Under the Curve, and terminal elimination half-life (T1/2) pre-dose and up to 12 hours post dose
Time frame: Day 14
Number of Participants with Adverse Events as a Measure of Safety
Time frame: From signing of informed consent through 21 days following study drug administration
Change in C-reactive Protein (CRP) levels
Time frame: Screening and/or Day 1 of each treatment period
The record gives a start of Jul 2012, a primary completion of Aug 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Duvelisib